KPV is a tripeptide corresponding to residues 11–13 of α-melanocyte-stimulating hormone (α-MSH), a 13-residue post-translational product of proopiomelanocortin. It carries the C-terminal end of the parent hormone but not the His-Phe-Arg-Trp core message sequence that drives classical melanocortin-1 receptor signalling, which is why it is studied separately from pigmentation-active α-MSH analogues such as Melanotan II. PubChem CID 125672 confirms the all-L free-acid form: (2S)-2-[[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoic acid.

In vitro and rodent work has associated KPV with reduced nuclear translocation of NF-κB and lower transcription of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6. It has been examined in murine models of experimental colitis, in human keratinocyte culture systems, and in epithelial wound-closure assays. Reported uptake routes differ between studies: some describe melanocortin-receptor-dependent activity, others describe receptor-independent intracellular action following transport by the oligopeptide transporter PepT1.

The honest limitation is that the evidence base is entirely preclinical. There are no controlled human efficacy data, the mechanistic route is unresolved rather than merely under-characterised, and the pharmacokinetics and solution stability of the free tripeptide are poorly described in the public literature. Findings in colitis and keratinocyte models should not be read as establishing behaviour in any other system.